Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449521 | 0.79 | — | — | |
| SCHEMBL618831 | 0.71 | — | — | |
| SCHEMBL28415 | 0.70 | MAOA (0.41) | CA2 | |
| SCHEMBL11873619 | 0.68 | CHRNB2 (0.33) | CHRNB2CHRNA7CHRNA4HTR3ACA12 | |
| SCHEMBL2118218 | 0.68 | CYP19A1 (0.35) | — | |
| SCHEMBL15269272 | 0.68 | CHRNB2 (0.33) | CHRNB2CHRNA7CHRNA4HTR3ACA12 | |
| SCHEMBL1006653 | 0.68 | ACHE (0.46) | CHRNB2CHRNA7CHRNA4HTR3AP2RX7 | |
| SCHEMBL20897982 | 0.67 | ACHE (0.42) | CHRNB2CHRNA7CHRNA4HTR3AP2RX7 | |
| SCHEMBL16335020 | 0.67 | CHRNB2 (0.32) | CHRNB2CHRNA7CHRNA4HTR3ACA12 | |
| SCHEMBL8404349 | 0.67 | TSHR (0.37) | CA12CA1CA2CA9P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2024-05-21 | — | — | US | claimed |
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | claimed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | claimed |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | claimed |
| EP-3720858-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | claimed |
| US-20190284200-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-19 | — | — | US | claimed |
| WO-2019113359-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2019-06-13 | — | — | WO | claimed |
| US-20190040058-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-02-07 | — | — | US | claimed |
| US-20160009712-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | claimed |
| WO-2016007731-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | claimed |
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| WO-2015018814-A1 | SUBSTITUTED PYRAZOLO[1,5-A]-PYRIDINE-3-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-02-12 | — | — | WO | claimed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | claimed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| US-20100048539-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-25 | — | — | US | claimed |
| EP-2079729-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-07-22 | — | — | EP | claimed |
| WO-2008058037-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987588-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | ADRB3, ADRB1, ADRB2 | CHRNB2 37/4885CHRNA7 54/4885CHRNA4 52/4885 |
| US-20100048539-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | PDGFRB, PDGFRA, KIT | CHRNB2 2065/4885CHRNA7 2591/4885CHRNA4 3331/4885 |
| US-20190040058-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | CHRNB2 4210/4885CHRNA7 2999/4885CHRNA4 2762/4885 |
| US-20160009712-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | CHRNB2 4382/4885CHRNA7 3482/4885CHRNA4 2637/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | CHRNB2 4542/4885CHRNA7 4552/4885CHRNA4 4546/4885 |
| US-20190284200-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | CHRNB2 57/4885CHRNA7 90/4885CHRNA4 73/4885 |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | SYK, FCGRT, SSB | CHRNB2 4829/4885CHRNA7 4773/4885CHRNA4 4844/4885 |
| US-20200385395-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | CHRNB2 38/4885CHRNA7 55/4885CHRNA4 53/4885 |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | KDM5A, KDM1A, KDM1B | CHRNB2 4210/4885CHRNA7 2999/4885CHRNA4 2762/4885 |
| US-20220396579-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | CHRNB2 38/4885CHRNA7 55/4885CHRNA4 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.